NVP-CGM097 exhibits high selectivity for wild-type p53 and shows potent antiproliferative ability in colorectal cancer and osteosarcoma cells with wild-type p53.358 NVP-CGM097, combined with MEK inhibitors, activates the MAPK signaling pathway and attenuates acute myelogenous leukemia (AML) cell load.359 When combined with BET or Cdk4/6 inhibitors, NVP-CGM097 induces cell death in neuroblastoma or ER-positive breast cancer cells.360,361. Here, TP53 is linked to acute myeloid leukemia.